Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Comparison of Two Rotational Alignment Methods for Astigmatism Correction in SMILE Surgery

NCT07696468 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2026-07-13
Last updated
2026-07-15

Condition(s) studied

MyopiaRefractive Ametropia

Investigational drug(s) / intervention(s)

Device-assisted cyclotorsion control during SMILEManual limbal marking-guided cyclotorsion adjustment during SMILE

Device-assisted cyclotorsion control during SMILE: One eye of each participant will undergo SMILE using device-assisted cyclotorsion control with the OcuLign function of the VISUMAX 800 platform. During surgery, OcuLign will assist in identifying ocular rotation and guiding astigmatic axis alignment. Apart from the cyclotorsion adjustment method, the surgical parameters, lenticule design, suction procedure, postoperative medication, and follow-up schedule will be the same as those used for the fellow eye.

Manual limbal marking-guided cyclotorsion adjustment during SMILE: The fellow eye of each participant will undergo SMILE using manual limbal marking-guided cyclotorsion adjustment. Limbal reference marks will be made in the upright preoperative position, and intraoperative axis alignment will be manually adjusted according to the limbal marks and the surgical reference direction. Apart from the cyclotorsion adjustment method, the surgical parameters, surgical procedure, postoperative medication, and follow-up schedule will be the same as those used for the contralateral eye.

Study summary

Small incision lenticule extraction (SMILE) is a commonly used corneal refractive procedure for correcting myopia and myopic astigmatism. During astigmatism correction, eye rotation between the upright examination position and the supine surgical position may affect the alignment of the astigmatic treatment axis and may contribute to residual astigmatism after surgery.

Manual limbal marking is a commonly used method to guide cyclotorsion adjustment during refractive surgery. OcuLign is an assisted cyclotorsion control function of the VISUMAX 800 platform that helps identify ocular rotation and guide axis alignment during SMILE. However, direct clinical evidence comparing OcuLign-assisted cyclotorsion control with manual limbal marking during SMILE is limited.

This study is a single-center, prospective, randomized, masked, contralateral-eye non-inferiority trial. Adults aged 18 to 40 years with stable myopia and astigmatism who plan to undergo bilateral SMILE surgery will be enrolled. In each participant, one eye will receive SMILE with OcuLign-assisted cyclotorsion control, and the fellow eye will receive SMILE with manual limbal marking-guided cyclotorsion adjustment. The treatment assigned to the right eye will be determined by randomization.

The primary objective is to compare residual refractive astigmatism at 3 months after surgery between the two methods. Secondary outcomes include visual acuity, refractive predictability and stability, astigmatism vector analysis, higher-order aberrations, contrast sensitivity, patient-reported quality of vision, overall satisfaction, and safety outcomes. Participants will be followed for approximately 6 months after surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age range: 18 - 40 years old. Patients with myopic astigmatism and stable refractive status for \>= 1 year. 2. Normal corneal morphology in both eyes, with corneal thickness and other ocular parameters meeting the requirements for SMILE surgery. 3. Preoperative corrected distance visual acuity (CDVA) \>= 1.0 in both eyes. 4. Manifest refractive cylinder \>= 0.75 D in both eyes, with an interocular difference in absolute cylinder power \<= 1.00 D. 5. Both eyes can provide reliable preoperative upright-position image information required for astigmatic axis recognition, and are judged by the investigator to meet the requirements for OcuLign cyclotorsion recognition and axis alignment on the VISUMAX 800 platform. 6. Voluntary to undergo bilateral SMILE surgery on the VISUMAX 800 platform, understanding the random eye-assignment scheme and signing the informed consent form. Exclusion Criteria: 1. History of prior ocular surgery, significant ocular trauma, or presence of ocular diseases that may affect the safety of refractive surgery or the interpretation of study outcomes. 2. Irregular astigmatism or poor repeatability of bilateral astigmatism measurements, making reliable astigmatic axis analysis impossible. 3. Presence of strabismus, nystagmus, significant binocular vision abnormality, or any condition that may affect fixation or cooperation during examinations. 4. Severe systemic diseases that may affect ocular healing or surgical safety. 5. Females who are pregnant or lactating. 6. Inability to complete the required postoperative follow-up visits or questionnaire assessments.

Primary outcome measure(s)

  • Residual refractive astigmatism — 3 months after surgery
    Residual refractive astigmatism will be measured as the absolute manifest cylinder power in diopters at 3 months after SMILE. The primary analysis will compare residual refractive astigmatism between eyes treated with OcuLign-assisted cyclotorsion control and eyes treated with manual limbal marking-guided cyclotorsion adjustment to evaluate non-inferiority.

Trial sites (1)

FacilityCityRegionStatus
Zhongshan Ophthalmic Center Guangzhou Guangdong
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07696468 on ClinicalTrials.gov ↗ ← All trials in China